<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363051">
  <stage>Registered</stage>
  <submitdate>21/02/2013</submitdate>
  <approvaldate>25/02/2013</approvaldate>
  <actrnumber>ACTRN12613000224729</actrnumber>
  <trial_identification>
    <studytitle>The efficacy and tolerability of Galvus (Vildagliptin) compared to Sulfonylureas in patients with new onset diabetes after transplantation (NODAT)</studytitle>
    <scientifictitle>The efficacy and tolerability of Galvus (Vildagliptin) compared to Sulfonylureas in patients with new onset diabetes after transplantation (NODAT)</scientifictitle>
    <utrn />
    <trialacronym>VAT (Vildagliptin after transplant)</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>New onset diabetes after transplant</healthcondition>
    <healthcondition>Renal Transplant</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Arm A- Oral Tablet of Vildagliptin 50mg once daily or 50mg twice daily if kidney function is greater than eGFR 60ml/min, for 16 weeks </interventions>
    <comparator>Arm B- Oral tablet Gliclazide Modified release 60mg Once daily, for 16 weeks</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Hypoglycaemic events, defined as blood glucose &lt;3.9 mmol/L (with or without symptoms)</outcome>
      <timepoint>0 and 4 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1.	24 hour CGM done at baseline and in the last week of each 120 day treatment period to measure the composite endpoints of Vildagliptin compare with sulfonylurea
a.	mean afternoon blood glucose (1300 to 1900 pm)
b.	percentage time of glucose &gt;11mmol/L
c.	percentage time of glucose &lt; 3.9 mmol/L (hypoglycemia)</outcome>
      <timepoint>0 and 4 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2.	Efficacy
a.	Difference of glycaemic control markers from baseline to endpoint between Vildagliptin and sulfonylurea arms
1.	HbA1c - measured via whole blood assay
2.	Fasting Plasma Glucose - measured via a plasma assay
3.	Fructosamine - measured via serum assay
b.	Difference of fasting insulin (serum assay), c-peptide (serum assay) and glucagon (plasma assay) level from baseline to endpoint between Vidagliptin and sulfonylurea arms</outcome>
      <timepoint>0-4 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>3.	Safety
a.	Symptomatic episodes of hypoglycaemia
b.	BGL confirmed hypoglycaemia (&lt;3.9 mmol/L)
c.	eGFR, 
d.	Urine albumin:creatinine ratio
e.	Haemoglobin, white cell count
f.	Lipids
g.	Liver function tests
h.	Biopsy-proven acute rejection  
i.	Graft loss 
j.	Immunosuppressive drug levels (tacrolimus etc)</outcome>
      <timepoint>0-4 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1.	Renal transplant recipient
2.	Adult (18 years or older)
3.	New Onset Diabetes After Transplant (OGTT or random or fasting BSL &gt; WHO recommendation)
4.	HbA1c &lt;8.0%</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.	Diabetic at time of transplant
2.	Less than 3 months post-transplant
3.	Treatment with diabetic medications 
4.	eGFR &lt; 30 ml/min/m2
5.	Severe hyperglycemia HbA1c&gt;8.0%
6.	Active infection or inflammatory process
7.	Unstable cardiac disease
8.	Elevated alanine aminotransferase, aspartate aminotransferase, or creatine phosphokinase (more than 2 times upper limit of normal)
9.	Inability to give informed consent
10.	Pregnancy or breastfeeding, or, woman of child-bearing age not willing to use contraception during the study period
11.	Patient is participating or has participated in another clinical trial and/or is taking or has taken an investigational drug in the past 28 days
12.	Patient is unlikely or unable to comply with the visits scheduled in the protocol (e.g. due to excessive travel requirements)
13.	Exclusion criteria will comply with local label  product information sheet
14.	Allergy to vildagliptin</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Patients will be recruited through file review and direct referral from Nephrologists in the renal transplant outpatient department at Royal Prince Alfred Hospital. After signing the consent form, patients will go into 1 month of screening to ensure stable BGL levels. Patients will then be randomised as per the procedures below. It is not a blinded study.</concealment>
    <sequence>The patients will be randomised 1:1 to each group, stratified by time post-transplant (less than 6 months vs more than 6 months). The randomisation sequence will consist of computer-generated random permuted blocks of size 4-8. The sequence will be stored in numbered, sealed, opaque envelopes. The envelopes will be opened by non-study personnel following successful completion of screening.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/03/2013</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>48</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <postcode>2050 - Camperdown</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Sydney Local Health District</primarysponsorname>
    <primarysponsoraddress>Level 11  , KGV Building, 
Missenden Rd, Camperdown NSW 2050</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Novartis Pharmaceuticals Pty Ltd</fundingname>
      <fundingaddress>54 Waterloo Rd
North Ryde NSW 2111</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Diabetes is common after renal transplant and gliclazide is often used as a first line treatment. The objective of the trial is to show that Vildagliptin can be safely used to control hyperglycaemia, with less hypoglycaemic episodes than its comparator of Gliclazide. 48 participants will be randomly allocated to either the intervention arm of oral tablets of 50mg once daily or twice daily of vildalgliptin or to the comparator arm of oral tablet 60mg Gliclazide modified release once daily. The patients will be followed for 16 weeks to assess for hypoglyacaemic episodes and safety.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The SLHD Ethics Review Committee (RPAH Zone)</ethicname>
      <ethicaddress>Research Development Office
Royal Prince Alfred Hospital
Missenden Road
CAMPERDOWN NSW 2050</ethicaddress>
      <ethicapprovaldate>18/12/2012</ethicapprovaldate>
      <hrec>X12-0306</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Steve Chadban</name>
      <address>Renal Medicine
Level 6 West
Royal Prince Alfred Hospital
Missenden Rd, Camperdown NSW 2050</address>
      <phone>+61 2 9515 6600</phone>
      <fax>+61 2 9515 6329</fax>
      <email>steve.chadban@sswahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Georgia Whitman</name>
      <address>Transplant Ambulatory Care
Lvl 9, Building 89
Royal Prince Alfred Hospital
Missenden Rd
Camperdown NSW 2050</address>
      <phone>+61 2 9515 7618</phone>
      <fax>+61 2 9515 6329</fax>
      <email>georgia.whitman@sswahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Georgia Whitman</name>
      <address>Transplant Ambulatory Care
Lvl 9, Building 89
Royal Prince Alfred Hospital
Missenden Rd
Camperdown NSW 2050</address>
      <phone>+61 2 9515 7618</phone>
      <fax>+61 2 9515 6329</fax>
      <email>georgia.whitman@sswahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Steven Chadban</name>
      <address>Renal Medicine
Level 6 West
Royal Prince Alfred Hospital
Missenden Rd, Camperdown NSW 2050</address>
      <phone>+61 2 9515 6600</phone>
      <fax>+61 2 9515 6329</fax>
      <email>steve.chadban@sswahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>